The investigators aim to explore the efficacy of [90Y-DOTA]-TOC and [177LuDOTA]-TOC therapy
in advanced neuroendocrine cancer. Therefore, the investigators assess response, survival and
long-term safety profile of systemic [90Y-DOTA]-TOC and [177LuDOTA]-TOC treatment in
metastasized neuroendocrine cancer patients. Adverse events are assessed according to the
criteria of the National Cancer Institute. Survival analyses are performed using multiple
regression models.